Ask your questionclose
* - Required fields

Genetic testing of hereditary cancer

The number of people suffering from cancer is growing every year in Latvia and in the world. Depending on the localization, the inherited tumors are diagnosed in 5-30% of cancer patients. Since the family history is not always complete, the assumption of the hereditary tumor should be based on tumor histology or suspicion of the hereditary cancer. One of the most known and described hereditary tumors is hereditary breast cancer and ovarian cancer. Hereditary cases of breast cancer and ovarian cancer account for about 20-30% of all cases of breast cancer. 40-50% of them are associated with changes in the BRCA1 and BRCA2 genes. According to various studies, the frequency of clinically significant variants of the BRCA1 and BRCA2 genes is 5-10% in patients with breast cancer, with more changes observed in patients under the age of 40 years. There are several allelic variants of BRCA1 and BRCA2 in Latvia, found in patients with breast cancer, who have a family history of cancer, or with an unclear family history of cancer. These variants are found not only in Latvia, but also in the world. One of them, the unique variant in the BRCA2 gene was found only in the Latvian population. Determination of allelic variants of BRCA1 and BRCA2 may be important not only for choosing the right treatment tactics, but also for determining the risks of the disease for the patient's family members. It is possible to choose the right tactics for the timely diagnosis of the disease or even avoid it knowing these risks.

Centre for Reproductive Genetics of iVF Riga clinic offers to determine the probability of hereditary cancer.

Four different testing options are available for hereditary breast cancer diagnosis, which allows to identify possible risks quickly and safely.
1. Determination of BRCA1 and BRCA2 hereditary mutations includes allelic variants BRCA1 c.68_69delAG, c.181T>G, c.4035delA, c.5266dupC and BRCA2 c.658delGT, c.646delG, which are the most common, and allows to diagnose the majority of patients with hereditary breast and ovarian cancer.
The price of this panel is 185 euros.
However, determination of the most common allelic variants does not guarantee that the changes aren't found anywhere else in the gene.
2. Therefore, full sequencing of BRCA1 / BRCA2  is possible that tests the entire gene completely. iVF Riga Genetic centre uses Next Generation Sequencing (NGS), the most advanced molecular biology method, to determine what changes are found in the BRCA1 and BRCA2 genes.
The price of this analysis is 700 euros.
3. Using both of the above methods, it is possible to determine the point changes that occur most often, affecting gene activity. However, point changes are not always detected. In such cases, it is also recommended to determine large deletions and insertions in the BRCA1 and BRCA2 genes that can cause breast or ovarian cancer. One of the most accurate methods is MLPA (Multiplex Ligation Probemix Amplification), which can detect such changes in genes that can not be determined by other methods.
The price of this analysis is 400 euros.
4. Since the development of breast cancer is determined not only by changes in BRCA1 and BRCA2 genes, but also in various other genes, besides, breast cancer can develop within other hereditary tumor syndromes, it is possible to test 111 different genes using the NGS method. NGS allows to determine the maximum possible variants that can lead to the development of tumors. This panel is recommended not only for hereditary breast / ovarian cancer, but also in the case of various other tumors, such as Lynch syndrome, or hereditary nonpolyposis colorectal cancer, Li-Fraumeni syndrome, Cowden syndrome, Fanconi anemia, various kinds of hereditary intestinal polyposis with high risk of malignancies, etc. This test can help to determine whether there is an increased risk of cancer developing in an earlier age than the population's average.
The price of this test is 1200 euros.

Your doctor will determine the best testing variant for you, or you can also consult a qualified specialist here in the clinic iVF Riga.

Carrying out any testing in our clinic, you get not only an incomprehensible combination of letters and numbers, but also an explanation, what means each of the detected clinically significant or possible clinical changes, as well as a full interpretation for each of these options. An experienced and reliable team of geneticists works in our clinic; our genetic laboratory is equipped with the latest technological achievements in the field of molecular genetics. Clinic iVF Riga also offers consultations with a geneticist who, in case of a positive answer, will explain what risks exist for close relatives, how to assess these risks and how to proceed.
It is possible to preserve own genetic material (eggs, ovarian tissues, semen) in our clinic if oncotherapy is required (some types of oncotherapy may harm germ cells, excluding the possibility of creating offspring in the future).
As an option for family planning, if hereditary tumor syndrome with a specific mutation is confirmed, it is possible to apply PGT-M, or preimplantation genetic testing for monogenic diseases, to give birth to a child not at increased risk of developing tumors. It would be particularly important for hereditary tumor syndromes, where cancer develops early and with 100% penetrance.

Contact our patient's coordinators!
Jelena Silkalna
Jelena Silkalna
Zita Gaidule (on maternity leave)
Zita Gaidule (on maternity leave)
Marina Valetko
Marina Valetko

Follow Us on social media!